Stocks News

LAST PRICE
10.5100
TODAY'S CHANGE (%)
Trending Up0.1500 (1.4479%)

Bid / Lots
10.4400/ 1
Ask / Lots
11.5200/ 1
Open / Previous Close
10.3100 / 10.3600
Day Range
Low 10.0500
High 10.7300
52 Week Range
Low 5.9900
High 12.3782
Volume
182,307
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Oct 21, 2024
- Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing, from 8:45AM ET on Monday Oct 21, 2024 by MT Newswires
  8:45AM ET on Monday Oct 21, 2024 by MT Newswires
  Companies Mentioned: AURA
  08:45 AM EDT, 10/21/2024 (MT Newswires) -- Elisabet de los Pinos, Director, President and Chief Executive Officer, on October 18, 2024, sold 24,992 shares in Aura Biosciences (AURA) for $300,839. Following the Form 4 filing with the SEC, Elisabet de...
Oct 18, 2024
- DJ Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data, from 11:38AM ET on Friday Oct 18, 2024 by Dow Jones
  11:38AM ET on Friday Oct 18, 2024 by Dow Jones
  Companies Mentioned: AURA
  
  By Adam L. Cataldo
  
  Shares of Aura Biosciences climbed after the company said it received positive early data for its cancer drug bel-sar.
  
  The stock rose 14% to $11.70 in early trading Friday, after hitting a new 52-week high of $12.37. Shares are up 28% in the last five days and 31% this year.
- DJ Aura Biosciences Is Maintained at Sector Outperform by Scotiabank, from 11:38AM ET on Friday Oct 18, 2024 by Dow Jones
  11:38AM ET on Friday Oct 18, 2024 by Dow Jones
  Companies Mentioned: AURA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AURA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 18, 2024 11:38 ET (15:38 GMT)
- DJ Aura Biosciences Up Over 13%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk, from 10:59AM ET on Friday Oct 18, 2024 by Dow Jones
  10:59AM ET on Friday Oct 18, 2024 by Dow Jones
  Companies Mentioned: AURA
  
  Aura Biosciences Inc (AURA) is currently at $11.63, up $1.34 or 13.02%
  
  --Would be highest close since Nov. 3, 2023, when it closed at $11.98
  
  --On pace for largest percent increase since Nov. 3, 2023, when it rose 16.09%
- DJ Aura Biosciences Is Maintained at Buy by BTIG, from 10:54AM ET on Friday Oct 18, 2024 by Dow Jones
  10:54AM ET on Friday Oct 18, 2024 by Dow Jones
  Companies Mentioned: AURA
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/AURA/analyst-ratings
  
  (END) Dow Jones Newswires
  
  October 18, 2024 10:54 ET (14:54 GMT)

Today
- DJ Anavex Life Sciences Is Maintained at Buy by EF Hutton, from 12 hours ago by Dow Jones
  12 hours ago by Dow Jones
  Companies Mentioned: AVXL
- DJ Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 15 hours ago by Dow Jones
  15 hours ago by Dow Jones
  Companies Mentioned: LRMR
- Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024, from 17 hours ago by Dow Jones
  17 hours ago by Dow Jones
  Companies Mentioned: AVXL
Yesterday
- *DJ Larimar Therapeutics 3Q Loss/Shr 24c >LRMR, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: LRMR
- Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones
  Companies Mentioned: LRMR
Oct 25, 2024
- DJ Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:38AM ET on Friday Oct 25, 2024 by Dow Jones
  6:38AM ET on Friday Oct 25, 2024 by Dow Jones
  Companies Mentioned: PRME
Oct 24, 2024
- Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: PRME
Oct 18, 2024
- DJ Anavex Life Sciences Price Target Maintained With a $40.00/Share by HC Wainwright & Co., from 7:13AM ET on Friday Oct 18, 2024 by Dow Jones
  7:13AM ET on Friday Oct 18, 2024 by Dow Jones
  Companies Mentioned: AVXL
Oct 17, 2024
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX(R)3-71 for the Treatment of Schizophrenia, from 7:30AM ET on Thursday Oct 17, 2024 by Dow Jones
  7:30AM ET on Thursday Oct 17, 2024 by Dow Jones
  Companies Mentioned: AVXL
Oct 16, 2024
- --Oppenheimer Initiates Coverage on Larimar Therapeutics With Outperform Rating, $26 Price Target, from 8:14AM ET on Wednesday Oct 16, 2024 by MT Newswires
  8:14AM ET on Wednesday Oct 16, 2024 by MT Newswires
  Companies Mentioned: LRMR

Aura Biosciences Inc
NASDAQ:AURAUnited States

Search Criteria

Oct 21, 2024

Aura Biosciences Insider Sold Shares Worth $300,839, According to a Recent SEC Filing, from 8:45AM ET on Monday Oct 21, 2024 by MT Newswires

Oct 18, 2024

DJ Aura Biosciences' Shares Touch 52-Week High on Positive Cancer Drug Data, from 11:38AM ET on Friday Oct 18, 2024 by Dow Jones

DJ Aura Biosciences Is Maintained at Sector Outperform by Scotiabank, from 11:38AM ET on Friday Oct 18, 2024 by Dow Jones

DJ Aura Biosciences Up Over 13%, on Pace for Largest Percent Increase Since November 2023 -- Data Talk, from 10:59AM ET on Friday Oct 18, 2024 by Dow Jones

DJ Aura Biosciences Is Maintained at Buy by BTIG, from 10:54AM ET on Friday Oct 18, 2024 by Dow Jones

Peers Headlines

Today

DJ Anavex Life Sciences Is Maintained at Buy by EF Hutton, from 12 hours ago by Dow Jones

DJ Larimar Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co., from 15 hours ago by Dow Jones

Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024, from 17 hours ago by Dow Jones

Yesterday

*DJ Larimar Therapeutics 3Q Loss/Shr 24c >LRMR, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results, from 7:00AM ET on Wednesday Oct 30, 2024 by Dow Jones

Oct 25, 2024

DJ Prime Medicine Price Target Maintained With a $10.00/Share by HC Wainwright & Co., from 6:38AM ET on Friday Oct 25, 2024 by Dow Jones

Oct 24, 2024

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones

Oct 18, 2024

DJ Anavex Life Sciences Price Target Maintained With a $40.00/Share by HC Wainwright & Co., from 7:13AM ET on Friday Oct 18, 2024 by Dow Jones

Oct 17, 2024

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX(R)3-71 for the Treatment of Schizophrenia, from 7:30AM ET on Thursday Oct 17, 2024 by Dow Jones

Oct 16, 2024

--Oppenheimer Initiates Coverage on Larimar Therapeutics With Outperform Rating, $26 Price Target, from 8:14AM ET on Wednesday Oct 16, 2024 by MT Newswires